Respiratory

Georgia Travlos, PharmD, discusses changes in influenza and respiratory syncytial virus immunizations and coadministration best practices.

Tezspire gains FDA approval as the first biologic for chronic rhinosinusitis with nasal polyps, offering improved patient outcomes.

The approval expands options for protecting infants from respiratory syncytial virus, which remains a leading cause of pediatric hospitalization.

A recent study reveals a heightened stroke risk in asthma patients recovering from severe COVID-19, emphasizing the need for proactive monitoring and management.

Pharmacists can help to address access issues, offer comprehensive medication counseling, and educate patients about disease management.

The study results highlight the importance of pneumococcal vaccination for patients with chronic respiratory diseases, particularly chronic obstructive pulmonary disease.

As their scope of practice continues to expand, researchers issue a survey on how community pharmacists conduct point-of-care testing for acute upper respiratory tract infections.

The recommendations are provided through the West Coast Health Alliance and pull from guidance from the American Academy of Pediatrics and other organizations.

As Walgreens senior director of immunizations, Samantha Picking, PharmD, delved into the evolution of pharmacies’ immunization services as well as their dedication to vaccine uptake.

Pharmacies play a significant role in influenza vaccination.

Researchers conducted a review of pharmacist interventions and their ability to impact the outcomes of patients with COPD.

Researchers determined the impact COVID-19 interventions had on Danish children’s incidence of RSV, influenza, and invasive pneumococcal disease.

This study is the first to compare 2 biologics for patients with chronic rhinosinusitis with nasal polyps and coexisting asthma.

There were more fires in the span of a 13-year period from 2005 to 2018 than in the previous 2 decades.

Approval comes from positive results in the MATINEE and METREX phase III trials, with data showing a significant reduction in annual rates of COPD exacerbations among patients.

Currently, the recommendation is for patients 75 years and older and those aged 60 to 74 years with an increased risk of severe respiratory syncytial virus.

Conflicting study findings show various associations between asthma and COVID-19; further data are needed.

Patients with pulmonary arterial hypertension (PAH) received the maximum tolerated dose of background therapy with sotatercept or the placebo to the therapy.

GSK announced its ANCHOR-1 and ANCHOR-2 phase 3 trial results for depemokimab’s efficacy and safety in treating patients with chronic rhinosinusitis with nasal polyps.

The results of this study show that the concurrent presence of asthma and obesity did not synergistically amplify inflammation in children with both asthma and overweight/obesity.

The next-gen molecular Metrix was given emergency use authorization for its ability to test for SARS-CoV-2 and influenza A and B viruses.

The combination includes 2 previously approved vaccines to target the 5 major serogroups of Neisseria meningitidis.

With the acceptance of the new drug application and granting priority review, the target action date is August 12, 2025.

In their exploration of 2 separate respiratory virus seasons, researchers examined the severity of illness for SARS-CoV-2, influenza, and respiratory syncytial virus.

As wildfires ravage Los Angeles County, pharmacists can provide crucial support to their patients.